Home | Global Trial Finder Janssen Global Trial Finder; World Without Disease Accelerator; Janssen Clinical Innovation; Precision Medicine Janssen Diagnostics
Janssen | 2022 Transparency Report Through the 2022 Janssen U S Transparency Report, we continue our legacy of contributing insights, data and real-world evidence to help inform and advance policy solutions to create a more sustainable, equitable and innovative healthcare system
Janssen Submits New Drug Application to U. S. FDA Seeking Approval of . . . RARITAN, NJ, May 30, 2023 – The Janssen Pharmaceutical Companies of Johnson Johnson announced today the submission of a New Drug Application (NDA) to the U S Food and Drug Administration (FDA) seeking approval of an investigational single tablet combination therapy of macitentan 10mg and tadalafil 40mg (M T STCT) for the long-term
How can we help you today? - connect. janssen. com This website is published by Janssen-Cilag Pty Limited (Janssen-Cilag), which is solely responsible for its content It is intended for Global healthcare professionals Changes to your country will result in data loss
A Phase 1 2 Study of Bleximenib in Participants With Acute Leukemia The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 (Part 1 [Dose Escalation] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion) The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D